Growing Market Presence Lunit has expanded to over 330 screening sites across the Americas, supporting approximately one million mammograms annually, indicating a strong foothold in the North American AI-driven cancer screening market and potential for expanded sales pipelines.

Advanced Regulatory Approval The recent FDA clearance of its next-generation 3D mammography AI underscores Lunit's commitment to regulatory compliance and positions it well to approach U.S. healthcare providers seeking proven, authorized AI solutions for breast cancer detection.

Innovation and Research Leadership Lunit presented six AI studies at major industry events such as AACR and ECR, demonstrating its strong research backing, which can be leveraged to build credibility and attract hospitals and research institutions interested in cutting-edge cancer diagnostics.

Robust Clinical Adoption Accelerating clinical adoption across the U.S. and full-scale deployment of AI-powered breast cancer ecosystems suggest increasing acceptance of Lunit’s solutions, creating opportunities to upsell or expand within existing customer networks and new healthcare facilities.

Strategic Collaborations Partnerships like the integration with CellCarta's pathology network and collaborations at prominent industry events indicate Lunit’s focus on strategic alliances, which can facilitate joint sales efforts and open access to broader markets in oncology and diagnostic services.